Genmab Completes Acquisition of ProfoundBio
May 21, 2024 11:06 ET
|
Genmab A/S
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cashAcquisition gives Genmab worldwide rights to three candidates in clinical development, including...
Transactions in Connection with Share Buy-back Program
May 21, 2024 07:19 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14, 2024 10:02 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development programThree oral...
Transactions in Connection with Share Buy-back Program
May 13, 2024 10:09 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
May 07, 2024 14:27 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. ...
Transactions in Connection with Share Buy-back Program
May 06, 2024 10:01 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Genmab Announces Financial Results for the First Quarter of 2024
May 02, 2024 11:01 ET
|
Genmab A/S
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024 18:40 ET
|
Genmab A/S
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient...
Transactions in Connection with Share Buy-back Program Genmab
April 29, 2024 04:24 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Transactions in Connection with Share Buy-back Program Genmab
April 22, 2024 03:30 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...